Role of the HPV DNA Test in Follow-up of Treated Cervical Intraepithelial Neoplasia in Bangladesh

  • Nessa, Ashrafun (Department of Obstetrics and Gynaecology, Bangabandhu Sheikh Mujib Medical University) ;
  • Rashid, Mohammad Harun Ur (Planning and Research Unit, Directorate General of Health Services) ;
  • Jahan, Munira (Department of Virology, Bangabandhu Sheikh Mujib Medical University) ;
  • Ferdous, Noor-E (Department of Obstetrics and Gynaecology, Bangabandhu Sheikh Mujib Medical University) ;
  • Nahar, Pervin Akhter Shamsun (Department of Obstetrics and Gynaecology, Bangabandhu Sheikh Mujib Medical University) ;
  • Chowdhury, Afroza (Department of Obstetrics and Gynaecology, Bangabandhu Sheikh Mujib Medical University)
  • Published : 2014.10.23


Background: Cervical cancer is a major public health problem in Bangladesh. Persistence of high risk human papillomavirus (HRHPV) influences the progression of the disease, with an important role in followup for cervical intraepithelial neoplasia (CIN). Objective: To establish application of high risk HPV DNA test in the follow-up of women after treatment of CIN. Materials and Methods: This cross-sectional and hospital based study was carried out among 145 CIN treated women during the previous six months to three years at the colposcopy clinic of Bangabandhu Sheikh Mujib Medical University, Dhaka, between January 2011 and June 2012. Pap smear and HPV samples were collected and colposcopy was performed to find out the persistence of the disease. Cervical samples obtained were tested for HPV DNA using the Hybrid Capture II (HC-II) test. A cervical biopsy was collected whenever necessary. The results were compared to assess the efficacy of different methods during follow up such as Pap smear, HPV test and colposcopy. Results: Mean age of the recruited women (n=145) was 33.6 (${\pm}7.6$), mean age of marriage was 16.8 (${\pm}2.9$) and mean age of 1st delivery was 18.8 (${\pm}3.5$) years. More than half had high grade CIN before treatment and 115 (79.3%) women were managed by LEEP and 20.7% were managed by cold coagulation. Among the 145 treated women, 139 were negative for HPV DNA and six of them (4.1%) were HPV positive. Sensitivity of Pap smear (40.0) and HPV DNA test (40.0) was poor, but specificity was quite satisfactory (>93.0) for all the tests. Conclusions: The high risk HPV DNA test can be an effective method of identifying residual disease. It can be added to colposcopy and this should be applied to all treated women attending for their first or second post-treatment follow-up visit at 6 months to one year, irrespective of the grade of treated CIN.


HPV DNA test;follow-up;treated CIN;Bangladesh


  1. Ahmed T, Ashrafunnessa, Rahman J (2008). Development of a visual inspection programme for cervical cancer prevention in bangladesh. Elsevier Reproductive Health Matters, 16, 78-85.
  2. Akhter PS, Uddin MM, Sharma SK (1998). Patterns of malignant neoplasm: A three year study. Bangladesh Med J, 27, 29-32.
  3. Coupe VM, Berkhof J, Verheijen RH, Meijer CJ (2007). Costeffectiveness of human papillomavirus testing after treatment for cervical intraepithelial neoplasia. BJOG, 114, 416-24.
  4. Agorastos T, Sotiriadis A, Chatzigeorgiou K (2010). Can HPV testing replace the pap smear? Ann N Y Acad Sci, 14, 51-6.
  5. Bollen LJM, Tjong-A-Hung S, van der Velden J, et al (1997). Clearance of human papillomavirus infection by treatment for cervical dysplasia. Sex Transm Dis, 24, 456-60.
  6. Bollen LJM, Tjong-A-Hung S, van der Velden J, et al (1996). Human papillomavirus dna after treatment of cervical dysplasia: low prevalence in normal cytologic smears. Cancer, 77, 2538-43.<2538::AID-CNCR17>3.0.CO;2-T
  7. Cuzick J (2000). Human papillomavirus testing for primary cervical cancer screening. JAMA, 283, 108-9.
  8. Elfgren K, Jacobs, Walboomers J M M, Meijer C J L M, Dillner J (2002). Rate of human papillomavirus clearance after treatment of cervical intraepithelial neoplasia. Obstet Gynecol, 100, 965-71.
  9. Ferlay J, Shin HR, Bray F, et al (2010). GLOBOCAN 2008: cancer incidence and mortality worldwide. IARC Cancer Base, Volume 10, Lyon, France: IARC Press;
  10. International Agency for Research on Cancer (2004). IARC handbooks on cancer prevention. Volume 10, Cervix Cancer Screening. IARC Press: Lyon.
  11. Jeong NH, Lee NW, Kim HJ, Kim T, Lee KW (2009). High-risk human papillomavirus testing for monitoring patients treated for high-grade cervical intraepithelial neoplasia. J Obstet Gynaecol Res, 35, 706-11.
  12. Kang WD, Oh MJ, Kim SM, et al (2010). Significance of human papillomavirus genotyping with high-grade cervical intraepithelial neoplasia treated by a loop electrosurgical excision procedure. Am J Obstet Gynecol, 203, 72.
  13. Martin-Hirsch P, Lilford R, Jarvis G, Kitchener HC (1999). Efficacy of cervical-smear collection devices: a systematic review and meta-analysis. Lancet, 354, 1763-70.
  14. Kitchener H, Walker P, Nelson L, et al (2008). HPV testing as an adjunct to cytology in the follow up of women treated for cervical intraepithelial neoplasia. BJOG, 15, 1001-7.
  15. Kjellberg L, Wadell G, Bergman F, et al (2000). Regular disappearance of the human papillomavirus genome after conization of cervical dysplasia by carbon dioxide laser. Am J Obstet Gynecol, 183, 1238-42.
  16. Manos MM, Kinney WK, Hurley LB, et al (1999). Identifying women with cervical neoplasia using human papillomavirus DNA testing for equivocal papanicolaou results. JAMA, 281, 1605-10.
  17. Mesher D, Szarewski A, Cadman L, et al (2010). Long-term follow-up of cervical disease in women screened by cytology and HPV testing: results from the HARTstudy. Br J Cancer, 27, 1405-10.
  18. Nessa A, Hussain MA, Rahman JN, et al (2010). Screening for cervical neoplasia in Bangladesh using visual inspection with acetic acid. Int J Gynaecol Obstet, 111, 115-8.
  19. Nessa A, Hussain MA, Rashid MH, et al (2013a). Role of print and audiovisual media in cervical cancer prevention in Bangladesh. Asian Pac J Cancer Prev, 14, 7607-11.
  20. Nessa A, Nahar KN, Begum SA, et al (2013b). Comparison between visual inspection of cervix and cytology based screening procedures in Bangladesh. Asian Pac J Cancer Prev, 14, 3131-7.
  21. Nobbenhuis MA, Meijer CJ, van den Brule AJ, et al (2001). Addition of high-risk HPV testing improves the current guidelines on follow up after treatment for cervical intraepithelial neoplasia. Br J Cancer, 84, 796-801.
  22. Soutter WP, de Barros Lopes A, Fletcher A, et al (1997). Invasive cervical cancer after conservative therapy for cervical intraepithelial neoplasia. Lancet, 349, 978-80.
  23. Paraskevaidis E, Arbyn M, Sotiriadis A, et al (2004). The role of HPV DNA testing in the follow up period after treatment for CIN: a systematic review of the literature. Cancer Treat Rev, 30, 205-11.
  24. Philip EC, Andrew GG, et al (2012). Clinical human papillomavirus detection forecasts cervical cancer risk in women over 18 years of follow-up. J Clin Oncol, 30, 3044-50.
  25. Ribaldone R, Boldorini R, Capuano A, et al (2010). Role of HPV testing in the follow-up of women treated for cervical dysplasia. Arch Gynecol Obstet, 282, 193-7.
  26. Young TK, Jong ML, Soo-Young H, et al (2010). Clearance of human papillomavirus infection after successful conization in patients with cervical intraepithelial neoplasia. Int J Cancer, 126, 1903-9.

Cited by

  1. Application of HPV DNA Testing in Follow-up after Loop Electrosurgical Excision Procedures in Northern Thailand vol.16, pp.14, 2015,
  2. Investigation of Transition Types of HPV DNA Test Results over Time in Korean Women vol.16, pp.8, 2015,